Leber’s Hereditary Optic Neuropathy (LHON) – Market outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2020 To 2030
Leber's
hereditary optic neuropathy (LHON) is characterized by rapid bilateral loss of
central vision. Primarily male patients are affected in early adult life. Optic
atrophy commonly appears within 3 months after the onset of the disease.
Relatives in the maternal line often show peripapillary microangiopathy typical
for LHON. In most cases, symptoms begin with one eye first, followed a few
weeks later by visual failure in the other eye. Extremely rarely there may be
neurologic abnormalities, such as peripheral neuropathy, postural tremor,
nonspecific myopathy, and movement disorders. LHON is caused by mutations in
mitochondrial DNA and is strictly transmitted by maternal inheritance. The
acute phase of LHON is characterized by a loss of central vision, including blurring
and reduced perception of color. Individuals usually lose vision in one eye
first and then lose vision in the other eye after two to three months. The
atrophic phase is characterized by bilateral optic atrophy, resulting in
lifelong blindness.
According
to Thelansis disease area data modeling the prevalence of LHON is ranges
between 1to 1.4 cases per 45,000, while the incidence of LHON is 1.2 in
1,000,000 population.
The competitive
landscape of Leber’s Hereditary Optic Neuropathy (LHON) includes country-specific
approved and pipeline therapies. Any asset/product-specific designation or
review and Accelerated Approval are tracked and supplemented with analyst
commentary.
KOLs insights of Leber’s
Hereditary Optic Neuropathy (LHON) across 8 MM market from the center of
Excellence/ Public/ Private hospitals participated in the study. Insights
around current treatment landscape, epidemiology, clinical characteristics,
future treatment paradigm, and Unmet needs.
Leber’s
Hereditary Optic Neuropathy (LHON) Market Forecast:
Patient Based Forecast Model (MS. Excel Based Automated Dashboard) which Data
Inputs with sourcing, Market Event, and Product Event, Country specific
Forecast Model, Market uptake and patient share uptake, Attribute Analysis,
Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
S. No Asset Company Stage
1 elamipretide (MTP-131) Stealth
BioTherapeutics Inc. Phase 2
2 GS010 GenSight
Biologics Phase 3
3 Visomitin Mitotech
SA Phase 1/2
Comments
Post a Comment